Literature DB >> 12171569

The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.

Pier F Cirillo1, Christopher Pargellis, John Regan.   

Abstract

The p38 mitogen activated protein (MAP) kinase is an integral enzyme involved in the production of a wide variety of pro-inflammatory cytokines from various cell types. The identification of this kinase and of the diaryl imidazole containing inhibitor, SB203580, initiated an intense discovery effort in this field. Numerous inhibitors were subsequently produced containing replacements for the imidazole, as well as some of the pharmacophores attached to it. During this time many other classes of potent p38 inhibitors emerged containing scaffolds and binding components not found in the diaryl imidazole group. This review summarizes nine of those classes. At least one of these classes requires the kinase to undergo reorganization prior to binding. From this diverse set of inhibitors four compounds have been reported advancing into human clinical trials.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171569     DOI: 10.2174/1568026023393390

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  13 in total

1.  Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study.

Authors:  Ravindra G Kulkarni; Palukuri Srivani; Garlapati Achaiah; G Narahari Sastry
Journal:  J Comput Aided Mol Des       Date:  2007-01-04       Impact factor: 3.686

2.  Cell-specific inhibition of p38alpha as a therapeutic strategy for inflammatory bowel disease.

Authors:  Eóin N McNamee; Colm B Collins; Matthew D P Lebsack; Jesús Rivera-Nieves
Journal:  Gastroenterology       Date:  2010-02-23       Impact factor: 22.682

3.  Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion.

Authors:  Yong Wang; Joshua Kellner; Lingbo Liu; Daohong Zhou
Journal:  Stem Cells Dev       Date:  2011-02-24       Impact factor: 3.272

4.  Requisite roles of LOX-1, JNK, and arginase in diabetes-induced endothelial vasodilator dysfunction of porcine coronary arterioles.

Authors:  Travis W Hein; Xin Xu; Yi Ren; Wenjuan Xu; Shu-Huai Tsai; Naris Thengchaisri; Lih Kuo
Journal:  J Mol Cell Cardiol       Date:  2019-04-20       Impact factor: 5.000

5.  Inhibition of p38 MAPK activity promotes ex vivo expansion of human cord blood hematopoietic stem cells.

Authors:  Jing Zou; Ping Zou; Jie Wang; Lei Li; Yong Wang; Daohong Zhou; Lingbo Liu
Journal:  Ann Hematol       Date:  2012-01-19       Impact factor: 3.673

6.  Golgi partitioning controls mitotic entry through Aurora-A kinase.

Authors:  Angela Persico; Romina Ines Cervigni; Maria Luisa Barretta; Daniela Corda; Antonino Colanzi
Journal:  Mol Biol Cell       Date:  2010-09-15       Impact factor: 4.138

7.  Studies of chirality effect of 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine on p38alpha by molecular dynamics simulations and free energy calculations.

Authors:  Quan Chen; Wei Cui; Mingjuan Ji
Journal:  J Comput Aided Mol Des       Date:  2009-08-12       Impact factor: 3.686

Review 8.  Chiral kinase inhibitors.

Authors:  Jian-kang Jiang; Min Shen; Craig J Thomas; Mathew B Boxer
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

9.  Evaluation of 3-(3-chloro-phenyl)-5-(4-pyridyl)-4,5-dihydroisoxazole as a novel anti-inflammatory drug candidate.

Authors:  Amanda Roberta Revoredo Vicentino; Vitor Coutinho Carneiro; Anderson de Mendonça Amarante; Claudia Farias Benjamim; Alcino Palermo de Aguiar; Marcelo Rosado Fantappié
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

10.  Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways.

Authors:  Jong-Hoon Lim; Jae-Suk Woo; Yung-Woo Shin
Journal:  Korean J Intern Med       Date:  2009-06-08       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.